The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence
Open accessAbstract
The novel coronavirus infection that initially found at the end of 2019 has attracted great attention. So far, the number of infectious cases has increased globally to more than 100 thousand and the outbreak has been defined as a pandemic situation, but there are still no “specific drug” available. Relevant reports have pointed out the novel coronavirus has 80% homology with SARS. In the difficulty where new synthesized drug cannot be applied immediately to patients, “conventional drug in new use” becomes a feasible solution. The first medication experience of the recovered patients in the US has led remdesivir to be the “specific drug”. China has also taken immediate action to put remdesivir into clinical trials with the purpose of applying it into clinical therapeutics for Corona Virus Disease 2019 (COVID-19). We started from the structure, immunogenicity, and pathogenesis of coronavirus infections of the novel coronavirus. Further, we analyzed the pharmacological actions and previous trials of remdesivir to identify the feasibility of conducting experiments on COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Chan, J. F.-W., Yuan, S., Kok, K.-H., To, K. K.-W., Chu, H., Yang, J., Xing, F., Liu, J., Yip, C. C.-Y., Poon, R. W.-S., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30154-9 · Cited by 8,944
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897 · cited 1×
“At present, it has been proved that the binding affinity between the extracellular domain of the S protein of SARS-CoV-2 and ACE2 receptors is about 10–20 times higher than that of SARS-CoV, which may facilitate human-to-human transmission of SARS-CoV-2 [12].”
Pathological findings of COVID-19 associated with acute respiratory distress syndrome
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30076-x · Cited by 8,545 · cited 1×
“It manifests that the severe immune injury in this patient may be closely linked to the overactivation of T lymphocytes characterized by the increase of Th17 lymphocytes and the high cytotoxicity of CD8 T lymphocytes [19].”
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients
Zou, L., Ruan, F., Huang, M., Liang, L., Huang, H., Hong, Z., Yu, J., Kang, M., Song, Y., Xia, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2001737 · Cited by 4,810
Emerging coronaviruses: Genome structure, replication, and pathogenesis
Chen, Y., Liu, Q., & Guo, D. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25681 · Cited by 3,062
Xu, X., Chen, P., Wang, J., Feng, J., Zhou, H., Li, X., Zhong, W., & Hao, P. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1637-5 · Cited by 2,205
Sheahan, T. P., Sims, A. C., Leist, S. R., Schäfer, A., Won, J., Brown, A. J., Montgomery, S. A., Hogg, A., Babusis, D., Clarke, M. O., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13940-6 · Cited by 1,738
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,661
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
Mulangu, S., Dodd, L. E., Davey, R. T., Tshiani Mbaya, O., Proschan, M., Mukadi, D., Lusakibanza Manzo, M., Nzolo, D., Tshomba Oloma, A., Ibanda, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910993 · Cited by 1,605
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Warren, T. K., Jordan, R., Lo, M. K., Ray, A. S., Mackman, R. L., Soloveva, V., Siegel, D., Perron, M., Bannister, R., Hui, H. C., et al. (2016) · Nature · doi:10.1038/nature17180 · Cited by 1,556
Agostini, M. L., Andres, E. L., Sims, A. C., Graham, R. L., Sheahan, T. P., Lu, X., Smith, E. C., Case, J. B., Feng, J. Y., Jordan, R., et al. (2018) · mBio · doi:10.1128/mbio.00221-18 · Cited by 1,416
Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome
WONG, C. K., LAM, C. W. K., WU, A. K. L., IP, W. K., LEE, N. L. S., CHAN, I. H. S., LIT, L. C. W., HUI, D. S. C., CHAN, M. H. M., CHUNG, S. S. C., et al. (2004) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2004.02415.x · Cited by 1,274
de Wit, E., Feldmann, F., Cronin, J., Jordan, R., Okumura, A., Thomas, T., Scott, D., Cihlar, T., & Feldmann, H. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922083117 · Cited by 887
Gordon, C. J., Tchesnokov, E. P., Feng, J. Y., Porter, D. P., & Götte, M. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ac120.013056 · Cited by 850
COVID-19 control in China during mass population movements at New Year
Chen, S., Yang, J., Yang, W., Wang, C., & Bärnighausen, T. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30421-9 · Cited by 818
Morse, J. S., Lalonde, T., Xu, S., & Liu, W. R. (2020) · ChemBioChem · doi:10.1002/cbic.202000047 · Cited by 776
Zhang, H., Kang, Z., Gong, H., Xu, D., Wang, J., Li, Z., Cui, X., Xiao, J., Meng, T., Zhou, W., et al. (2020) · doi:10.1101/2020.01.30.927806 · Cited by 658
MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile
Mahallawi, W. H., Khabour, O. F., Zhang, Q., Makhdoum, H. M., & Suliman, B. A. (2018) · Cytokine · doi:10.1016/j.cyto.2018.01.025 · Cited by 558
ACE2 Expression in Kidney and Testis May Cause Kidney and Testis Infection in COVID-19 Patients
Fan, C., Lu, W., Li, K., Ding, Y., & Wang, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2020.563893 · Cited by 542
Kim, J. Y., Choe, P. G., Oh, Y., Oh, K. J., Kim, J., Park, S. J., Park, J. H., Na, H. K., & Oh, M.-D. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e61 · Cited by 404
The Pathogenesis of Ebola Virus Disease
Baseler, L., Chertow, D. S., Johnson, K. M., Feldmann, H., & Morens, D. M. (2017) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100506 · Cited by 404
Remdesivir as a possible therapeutic option for the COVID-19
Al-Tawfiq, J. A., Al-Homoud, A. H., & Memish, Z. A. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101615 · Cited by 367
Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge
Lo, M. K., Feldmann, F., Gary, J. M., Jordan, R., Bannister, R. M., Cronin, J., Patel, N. R., Klena, J. D., Nichol, S. T., Cihlář, T., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau9242 · Cited by 293
Pedersen, N. C., Perron, M., Bannasch, M., Montgomery, E., Murakami, E., Liepnieks, M., & Liu, H. (2019) · Journal of Feline Medicine and Surgery · doi:10.1177/1098612x19825701 · Cited by 269
[Potential antiviral therapeutics for 2019 Novel Coronavirus].
Li, H., Wang, Y., Xu, J. Y., & Cao, B. (2020) · PubMed · doi:10.3760/cma.j.issn.1001-0939.2020.0002 · Cited by 180
Nucleosides for the treatment of respiratory RNA virus infections
Jordan, P. C., Stevens, S., & Deval, J. (2018) · Antiviral chemistry & chemotherapy · doi:10.1177/2040206618764483 · Cited by 145
Qiu, T., Mao, T., Wang, Y., Zhou, M., Qiu, J., Wang, J., Xu, J., & Cao, Z. (2020) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2020.01.003 · Cited by 42
Cited by
Environmental perspective of COVID-19
Saadat, S., Rawtani, D., & Hussain, C. M. (2020) · Science of The Total Environment · doi:10.1016/j.scitotenv.2020.138870 · Cited by 980
Sharma, A., Ahmad Farouk, I., & Lal, S. K. (2021) · Viruses · doi:10.3390/v13020202 · Cited by 703
A brief review of socio-economic and environmental impact of Covid-19
Bashir, M. F., MA, B., & Shahzad, L. (2020) · Air Quality, Atmosphere & Health · doi:10.1007/s11869-020-00894-8 · Cited by 269
Sabaka, P., Koščálová, A., Straka, I., Hodosy, J., Lipták, R., Kmotorková, B., Kachlíková, M., & Kušnírová, A. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-05945-8 · Cited by 130
Metadata
- Authors
- Cao, Y.-C., Deng, Q.-X., & Dai, S.-X.
- Venue
- Travel Medicine and Infectious Disease
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 35
- Pages
- 101647
- ISSN
- 1477-8939 (ISSN-L)
- OpenAlex
- W3013667078
- Cited by
- 320
- References
- 32
- FWCI
- 8.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.